# VERTEX THE SCIENCE of POSSIBILITY




Innovating to Accelerate the Delivery of Transformative Therapies to Patients

PQRI/FDA Conference on Advancing Product Quality April 9, 2019 Stephanie Krogmeier









## Three Essential Components of Innovation

Commit to a purpose

· Be brave

Be different





#### **Our Vision**

Vertex is a global biotechnology company that invests in **scientific innovation** to create **transformative medicines** for people with **serious diseases** with a focus on **specialty markets** 





#### **Our Mission and Values**

Innovate to Redefine Health and Transform People's Lives with New Medicines





#### Innovation is our Lifeblood

#### VERTEX'S COMMITMENT TO RESEARCH & DEVELOPMENT

We believe scientific innovation is the key to creating value. Bringing together the brightest minds, investing in science and taking smart risks, we strike at the core of serious diseases to transform the lives of people around the world.










## Vertex's Noteworthy Industry Firsts





# Three Essential Components of Innovation

Commit to a purpose

Be brave

Be different





"Traditional manufacturing...could delay acceleration of development

"The innovator advantage is not just drug discovery, it is also with manufacturing. The pharmaceutical industry (unlike many other industries) does not often see innovation in manufacturing as a key strategic advantage. The few firms who do, will see immense value in prioritizing this." – Dr. Janet Woodcock

"No matter how your,"
and how important the unmet need,
approval also hinges on whether you have
a manufacturing facility ready to go and a
a manufacturing up production so
plan in place for scaling up production."
you can manufacture your new drug..."



# CMC Challenges for Expedited Development and Review

Commercial
manufacturing
process and
formulation need to
be developed early
to align with the
accelerated clinical
development
program

Scale up issues
need to be
addressed to ensure
availability of quality
product at the time of
approval

A plan for validation and stability studies needs to be developed to keep these activities off critical path to approval

# CMC Challenges for Expedited Development are Valid





# Vertex's Continuous **Powder In Manufacturing Rig** Day 1 AM **Much Smaller Footprint** Smaller scale equipment All unit ops in one facility




**Coated Tablets Out** Day 1 AM

PAT Based Control Strategy => IPCs + RTR1

## **Health Authority Interactions Opportunities**

- Innovation in a regulated environment requires global health authority alignment
- Communication and transparency are critical for building relationships and establishing partnerships with Health Authorities
- Use all available options and avenues to interact with Health Authorities early and often





#### From Business Drivers to CM Realization







Full support from the highest levels of management

CM central to development strategy to get breakthrough therapies to patients

Highly motivated and dedicated team



# Three Essential Components of Innovation


Commit to a purpose

Be brave

Be different







#### Turns out.....

• In order to be successful one must always be different

McKinsey found that companies with more diverse workforces

perform better financially




More likely to outperform

Gender diverse companies

35% More likely to outperform

Ethnically diverse companies





## Diversity is Different

#### Inherent

- Gender
- Race
- Age
- Religious background...

### Acquired


- Cultural fluency
- Global mindset
- Language skills
- Broad life experiences ...





Biotech Companies Founded 1000's

# Of all biotech companies, how many have internally discovered & developed four or more approved medicines (NMEs)?



# Acknowledgements

- Vertex Team
  - Pharmaceutical Sciences
  - Technical Operations
  - Supply Chain Management
  - Quality
  - CMC Regulatory



Our CMOs, Suppliers, and Research Collaborators



#### Questions

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets

Stephanie Krogmeier, Ph.D.
Vice President, Global Regulatory Affairs
Vertex Pharmaceuticals
50 Northern Avenue
Boston, MA 02210
stephanie\_krogmeier@vrtx.com
www.vrtx.com

# Innovate to Redefine Health and Transform People's Lives with New Medicines

